SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-23-113014
Filing Date
2023-10-31
Accepted
2023-10-31 17:21:52
Documents
12
Period of Report
2023-10-26
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2329533d1_8k.htm   iXBRL 8-K 27638
  Complete submission text file 0001104659-23-113014.txt   201120

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA fwbi-20231026.xsd EX-101.SCH 3027
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE fwbi-20231026_lab.xml EX-101.LAB 34240
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE fwbi-20231026_pre.xml EX-101.PRE 22367
6 EXTRACTED XBRL INSTANCE DOCUMENT tm2329533d1_8k_htm.xml XML 3318
Mailing Address 777 YAMATO ROAD SUITE 502 BOCA RATON FL 33431
Business Address 777 YAMATO ROAD SUITE 502 BOCA RATON FL 33431 561-589-7020
First Wave BioPharma, Inc. (Filer) CIK: 0001604191 (see all company filings)

IRS No.: 464993860 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37853 | Film No.: 231365796
SIC: 2834 Pharmaceutical Preparations